Εμφανίζονται 1 - 20 Αποτελέσματα από 35 για την αναζήτηση '"2006"', χρόνος αναζήτησης: 0,12δλ Περιορισμός αποτελεσμάτων
  1. 1
    “…Following an application from Greenleaf Medical AB, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Sweden, the EFSA Panel on Nutrition, Novel Foods and Food allergens (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Appethyl® and reduction of body weight. …”
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Online Άρθρο Κείμενο
    Appethyl® and reduction of body weight: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006
  2. 2
    “…Following an application from Unilever NV, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Ireland, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to black tea and improvement of attention. …”
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Online Άρθρο Κείμενο
    Black tea and improvement of attention: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006
  3. 3
    “…Following an application from Suomen Terveysravinto Oy, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Finland, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to curcumin and normal functioning of joints. …”
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Online Άρθρο Κείμενο
    Curcumin and normal functioning of joints: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006
  4. 4
    “…Following an application from Pharmactive Biotech Products, S.L. submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Spain, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to affron(®) and contributes to maintain a healthy mood. …”
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Online Άρθρο Κείμενο
    Affron(®) and increase in positive mood: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006
  5. 5
    “…Following an application from Anxiofit Ltd., submitted for authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of Hungary, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Anxiofit‐1 and reduction of subthreshold and mild anxiety. …”
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Online Άρθρο Κείμενο
    Anxiofit‐1 and reduction of subthreshold and mild anxiety: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006
  6. 6
    “…Following an application from BENEO GmbH submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to isomaltulose and normal energy‐yielding metabolism. …”
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Online Άρθρο Κείμενο
    Isomaltulose and normal energy‐yielding metabolism: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006
  7. 7
    “…Following an application from analyze & realize GmbH submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Ireland, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to GlycoLite™. …”
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Online Άρθρο Κείμενο
    GlycoLite™ and helps to reduce body weight: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006
  8. 8
    “…Following an application from Lonza Ltd., submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to L‐carnitine and normal lipid metabolism. …”
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Online Άρθρο Κείμενο
    L‐carnitine and contribution to normal lipid metabolism: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006
  9. 9
    “…Following an application from Han‐Biotech GmbH, submitted for authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Symbiosal(®), lowering of blood pressure and reduced risk of hypertension. …”
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Online Άρθρο Κείμενο
    Symbiosal(®) and lowering of blood pressure and reduced risk of hypertension: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006
  10. 10
    “…Following an application from Unilever NV, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Ireland, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to black tea and maintenance of normal endothelium‐dependent vasodilation. …”
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Online Άρθρο Κείμενο
    Black tea and maintenance of normal endothelium‐dependent vasodilation: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006
  11. 11
    “…Following an application from Procter & Gamble BV pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of Belgium, the Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to choline and contribution to normal liver function of the foetus and exclusively breastfed infant. …”
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Online Άρθρο Κείμενο
    Choline and contribution to normal liver function of the foetus and exclusively breastfed infants: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006
  12. 12
    “…Heinz Supply Chain Europe B.V. submitted for authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Nutrimune and immune defence against pathogens in the gastrointestinal (GI) tract and upper respiratory tract (URT). …”
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Online Άρθρο Κείμενο
    Nutrimune and immune defence against pathogens in the gastrointestinal and upper respiratory tracts: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006
  13. 13
    “…Following an application from Laboratoires Nutrition et Cardiométabolisme, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Stablor(®) and decrease in visceral fat while preserving lean mass. …”
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Online Άρθρο Κείμενο
    Stablor(®) and reduction of visceral fat while maintaining lean mass: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006
  14. 14
    “…Heinz Supply Chain Europe B.V., submitted for authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to ‘Nutrimune(®)’ and immune defence against pathogens in the gastrointestinal (GI) tract and upper respiratory tract (URT). …”
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Online Άρθρο Κείμενο
    ‘Nutrimune(®)’ and immune defence against pathogens in the gastrointestinal and upper respiratory tracts: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006
  15. 15
    “…Following an application from Loc Troi group, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Vibigaba (germinated brown rice) and contribution to the maintenance of normal blood pressure. …”
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Online Άρθρο Κείμενο
    Vibigaba (germinated brown rice) and maintenance of normal blood pressure: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006
  16. 16
    “…Following an application from Specialised Nutrition Europe (formerly IDACE), submitted for authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to vitamin C and protection of DNA, proteins and lipids from oxidative damage. …”
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Online Άρθρο Κείμενο
    Vitamin C and protection of DNA, proteins and lipids from oxidative damage: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006
  17. 17
    “…Following an application from Tchibo GmbH submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Coffee C21 and protection of DNA from strand breaks. …”
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Online Άρθρο Κείμενο
    Coffee C21 and protection of DNA from strand breaks: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006
  18. 18
    “…Following an application from Loc Troi group, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Vibigaba (germinated brown rice) and contribution to the maintenance of normal blood cholesterol concentrations. …”
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Online Άρθρο Κείμενο
    Vibigaba (germinated brown rice) and maintenance of normal blood cholesterol concentration: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006
  19. 19
    “…Following a request from the European Commission, the GMO Panel assessed additional information related to the application for authorisation of food and feed containing, consisting of and produced from genetically modified (GM) maize 3272 (EFSA‐GMO‐UK‐2006‐34). The applicant conducted new agronomic, phenotypic and compositional analysis studies on maize 3272 and assessed the allergenic potential of AMY797E protein, addressing elements that remained inconclusive from previous EFSA opinion issued in 2013. …”
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Online Άρθρο Κείμενο
    Statement complementing the EFSA Scientific Opinion on application (EFSA‐GMO‐UK‐2006‐34) for authorisation of food and feed containing, consisting of and produced from genetically modified maize 3272
  20. 20
    “…Following an application from Laboratoire Nurilia submitted for authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to ‘Condensyl(®) and decreases sperm DNA damage. …”
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Λήψη πλήρους κειμένου
    Online Άρθρο Κείμενο
    Condensyl(®) and decreases sperm DNA damage which is a risk factor for male infertility: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006
Εργαλεία αναζήτησης: Λήψη RSS